Novocure

NovoCure Limited is an oncology company focused on the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) therapy, specifically through its flagship product, Optune. This innovative treatment targets solid tumors, including glioblastoma, by utilizing electric fields to disrupt cancer cell division, thereby slowing or reversing tumor progression. In addition to Optune, the company is advancing a pipeline of products, including those in Phase 2 and Phase 3 clinical trials for various cancers such as brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. NovoCure markets its devices in the European Union, Japan, and other international markets, and has established collaborations to enhance its research and development efforts. Founded in 2000 and headquartered in Saint Helier, Jersey, NovoCure aims to provide effective treatment options for patients battling cancer through its innovative technology.